Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Glioblastoma 5Gliosarcoma 4Central Nervous System Neoplasms 4Oligodendroglioma 2Brain Neoplasms 2Astrocytoma 2Prolactinoma 1Pituitary Neoplasms 1Neuroblastoma 1Growth Hormone-Secreting Pituitary Adenoma 1Glioma 1Cognition Disorders 1Adenoma, Chromophobe 1Adenoma, Basophil 1Adenoma, Acidophil 1

Interventions

Temozolomide 1Surveys and Questionnaires 1Microarray Analysis 1DNA Methylation 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Growth Hormone-Secreting Pituitary Adenoma × DNA Methylation × CNS × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡